- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Mark Cziraky, PharmD, CLS: Biosimilar Utilization
Mark Cziraky, PharmD, CLS, vice president of research for Healthcore, explains why biosimilar utilization in the United States is low.
Transcript:
Are there gaps in knowledge about biosimilars that are impacting decision-making by stakeholders?
I think we’re not seeing the utilization because there’s not a lot marketed yet, so it’s tough to see what’s happening out there in the marketplace after you get real-world use of these products. From a standpoint of the approvals and the trials, you know they’re of course safe and effective from the standpoint of being biosimilars. The other piece of it is there may be some concerns about safety and the immunogenicity, but I don’t believe that’s having a significant impact on the use currently. It’s really just the amount that are available for use. Also, again, because there’s not a lot of competition in the marketplace, the ability to see significant cost-reductions that is hoped by these therapies has not yet been reached.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
